PEPR PROPSY is organizing PsyTech 2026, a national event dedicated to digital innovation and artificial intelligence in psychiatry, held under the High Patronage of Mr. Emmanuel MACRON, President of the French Republic, and under the patronage of the French Ministry of Higher Education and Research, the French Ministry of Health, Families, Autonomy and Persons with Disabilities, and the Hauts-de-France Regional Council.
This one-day event, organized in partnership with PEPR PROPSY Digital Health, will bring together researchers, clinicians, industry leaders, public institutions, investors, and representatives of people with lived experience of mental health conditions. Its ambition is to unite these stakeholders around the development and implementation of a strong French ecosystem for digital psychiatry.
Objectives of the event:
- Identify the scientific, regulatory, economic, and organizational barriers currently slowing the development and adoption of digital innovations in psychiatry.
- Foster collaboration among researchers, clinicians, industry, public institutions, investors, patient representatives, and individuals with lived experience.
- Promote public-private partnerships to accelerate innovation and ensure equitable access to new technologies.
- Strengthen the attractiveness of psychiatry for innovation and investment stakeholders.
- Advance practical, evidence-based, interoperable, and scalable digital solutions for research and clinical care.
- Contribute to the development of a shared national strategy for digital innovation and artificial intelligence in psychiatry.
In preparation for the event, several thematic working groups brought together experts from academia, healthcare, industry, government, and patient organizations to address the key challenges involved in building this emerging ecosystem. Topics included health data and digital phenotyping, artificial intelligence and clinical development, evaluation, regulation, business models, scaling, and integration into clinical practice. Their preliminary findings will be presented during the event and will contribute to the development of a National White Paper on Digital Innovation and Artificial Intelligence in Psychiatry.
Program highlights:
- A panel discussion on the key drivers for building a robust digital psychiatry ecosystem, featuring healthcare executives, elected officials, and European representatives.
- Presentations from the thematic working groups on: health data and digital phenotyping, artificial intelligence and clinical development and implementation and scaling.
- Presentation of the White Paper’s key recommendations and a call to action.
- Startup pitch sessions.
- Speed networking meetings between industry, innovation hubs, and academic stakeholders.
- Closing remarks by Mr. Xavier Bertrand, President of the Hauts-de-France Regional Council.
PsyTech 2026 offers a unique opportunity to foster dialogue, address the barriers to innovation, and help build a thriving digital psychiatry ecosystem in France.
The current schedule is available here.
B&A Biomedical is a young, dynamic startup that is firmly focused on innovation and passionate about technological and computational advances in the fields of healthcare and biology. Its primary goal is to develop new, customized solutions for analyzing data related to these rapidly evolving fields.
B&A Biomedical is the driving force behind the PELARGOS project, which uses artificial intelligence to analyze clinical data routinely collected in maternity wards in order to identify, from birth, children at risk of developing ASD. This research program, currently being conducted at several French university hospitals, could enable earlier and more effective psycho-educational intervention.
Callyope is developing a clinical AI platform dedicated to psychiatry, designed to support healthcare teams caring for patients with severe mental health disorders.
Its proprietary AI model is specifically trained on the unique characteristics of psychiatric language and speech, enabling greater reliability than general-purpose models. The platform combines documentation agents, which automate the creation of clinical summaries, medical reports, and correspondence, with clinical agents that provide objective data on patients’ progress. The platform notably includes CallyoVoice, a medical device capable of assessing symptom severity from just 30 seconds of speech. Callyope also aims to further develop this technology for remote patient monitoring.
The solution is sovereign and secure, with AI developed in-house, HDS-certified hosting, and ISO 27001 certification. It is already deployed across healthcare institutions in France.
Dalia is a medtech company founded in 2023 that develops digital medical devices for psychiatry, with an initial focus on depression. The company uses digital phenotyping, an approach that involves analyzing behavioral and physiological data collected passively via smartphones and connected devices, as well as active data from clinical questionnaires.
Using artificial intelligence algorithms, Dalia identifies digital biomarkers that enable the early detection of first depressive episodes, monitor treatment adherence, and predict relapses in real time. Its solutions provide healthcare professionals with a continuous and objective view of patients’ condition between appointments, facilitating earlier, more personalized, and more responsive care.
By integrating these technologies into the care pathway, Dalia aims to improve the quality of psychiatric care, reduce the risk of relapse, and optimize clinical outcomes while enhancing quality of life.
Dextrain, a company born out of clinical research, develops digital solutions for measuring, rehabilitating, and predicting neurological and neurocognitive deficits, combining precision motion sensors with artificial intelligence.
With NeuroScreen, a France 2030 award-winning project, Dextrain is extending this expertise to the field of psychiatry and the early diagnosis of psychotic disorders.
The solution generates a multidimensional neurodevelopmental score based on digital cognitive and motor assessments.
It helps identify vulnerabilities, refine the profiles of affected individuals, and assist clinicians in guiding and personalizing care early on, with the goal of reducing the duration of untreated psychosis.
Di&Care is a French digital health company, founded in June 2023 and incubated at Eurasanté in Lille, that develops new therapeutic solutions in the field of mental health.
Its first digital medical device, NOXXEA, is designed to treat chronic insomnia and is based on the principles of cognitive-behavioral therapy for insomnia (CBT-I), which is recommended as a first-line treatment.
Prescribed by a healthcare professional, NOXXEA offers a structured 28-day digital therapeutic program combining psychoeducation, therapeutic exercises, and personalized treatment pathways.
Initial real-world data, as well as the initial results from the REST-NOXXEA clinical trial, are positive and confirm the solution’s clinical potential with a view toward securing reimbursement, in order to make this new therapeutic approach accessible to as many patients with insomnia as possible.
Leopa is developing a digital therapeutic specifically designed for bipolar disorder. The solution combines longitudinal monitoring of mood, sleep, treatments, and other clinical indicators with early detection of signs of relapse, psychoeducation, and personalized therapeutic support. Leopa thus aims to empower patients while providing healthcare professionals with a more continuous view of their progress between appointments, in line with the principles of precision psychiatry and integrated care pathways.
Live-It is an immersive augmented reality solution designed to raise awareness and train students and healthcare professionals about psychiatric disorders and cognitive disabilities, in particular by simulating the symptoms of these conditions.
This unique approach aims to improve training, reduce stigma, increase empathy, and make psychiatry a more attractive field. Its innovation lies in the use of AR—which is more accessible and realistic than existing solutions—and in its inclusive approach that involves all stakeholders to ensure more humane care.
Manitty is a French DeepTech company founded in 2021 that specializes in neurotechnologies, digital medical devices, and artificial intelligence applied to healthcare.
Based in Lyon and founded by graduates of the École Polytechnique, it develops multimodal bio-monitoring solutions that measure and analyze physiological, cognitive, and neurophysiological states in real-world conditions. Its technologies, designed in collaboration with CNRS researchers and clinicians, are used in research, mental health, and hospital monitoring.
As a recipient of funding from several innovation programs (i-Lab, NATO DIANA, France 2030), Manitty aims to advance medical neurotechnologies to improve prevention, diagnosis, and follow-up care for those affected.
Neuralim is a French digital health startup founded in 2026 in Corrèze by psychiatrists. It is developing Clara, a digital pre-consultation assistant for psychiatry. Before the appointment, the patient receives a link and communicates with Clara—either verbally or in writing—from home and at their own pace; a family member or friend may also provide input. The psychiatrist receives a report and a summary, then generates letters to the primary care physician or a colleague with just a few clicks. Clara collects and organizes the patient’s statements without interpreting them or making a diagnosis: interpretation remains the responsibility of the physician. Hosted in France by an HDS-certified hosting provider and based on European AI models, the solution aims to free up the physician’s time for the actual consultation.
Founded in 2012 by Professor Yehezkel Ben-Ari, Neurochlore is a startup that is a pioneer in the study of the brain’s fundamental mechanisms. Through a unique approach, notably based on the concepts of Neuroarcheology and GABAergic Polarity, Neurochlore has shed new light on the crucial role of the excitation-inhibition balance in the development of a functional brain.
As a leader in several clinical trials for the treatment of ASD, Neurochlore recently launched the PRECIBUM project. This program harnesses the power of artificial intelligence to reanalyze clinical data and identify subgroups of individuals most likely to respond to treatment. This work demonstrates the potential of artificial intelligence to better account for the heterogeneity of certain disorders in future clinical trials and pave the way for precision medicine tailored to each patient’s profile.
Founded in 2018 by graduates of the École Polytechnique, Poppins is a company specializing in the development of rehabilitation tools for children with neurodevelopmental disorders. In particular, it is developing the digital medical device (DMD) of the same name, which takes the form of a video game that helps children with dyslexia improve their reading fluency—the primary indicator of this disorder.
This DMN has received a favorable opinion from the Haute Autorité de Santé (HAS) for early intervention and is now covered by the French national health insurance system under the PECAN program.
SÊMEIA is a French medtech company specializing in remote medical monitoring of patients with chronic conditions. Founded in 2017, the company develops digital solutions that enable healthcare teams to monitor patients remotely through the intelligent analysis of health data.
Deployed in more than 500 healthcare facilities, Sêmeia’s platform covers several specialties, including nephrology, cardiology, pulmonology, and mental health. Its flagship solution, NephroWise, is now recognized as the gold standard in renal telemonitoring in France.
The company continues to grow in France and across Europe, driven by a recent €21 million funding round. Sêmeia has been a member of Eurobiomed since 2019.
Sonomind is developing a medical device designed to treat treatment-resistant depression and other neurological and psychiatric disorders, using its revolutionary non-invasive ultrasound neuromodulation technology. With its breakthrough innovation, Sonomind precisely targets the deep brain structures involved in depression in a non-invasive and safe manner. This solution offers new hope to the tens of millions of people in Europe—and the 300 million people worldwide—who suffer from treatment-resistant depression, paving the way for effective treatments without side effects.
TOMO is a digital health company that combines human support, patient expertise, and data analysis to improve the patient experience and support continuity of care.
With TOMO Connect, the company offers structured peer support provided by selected, trained, and supervised peer supporters, complementing the work of healthcare professionals. This approach aims to strengthen patients’ autonomy and ability to take action in the face of daily challenges.
TOMO Insight organizes and analyzes data from care pathways, questionnaires, and interactions to better understand quality of life, the burden of treatment, barriers to treatment adherence, and signs of disengagement. These insights help healthcare providers identify unmet needs, tailor their support, and can inform real-world research projects.
The registration form is available here.
Are you a partner of our event? Find our promotional materials here. Feel free to share them on your platforms and with your network.
Read the press release here.
